|This Slide: #88 of 100|
Slide #88. Elanco, the animal health division of Eli Lilly and Company — Lohmann Animal Health
Elanco, the animal health division of Eli Lilly and Company (NYSE:LLY)
Lohmann Animal Health
Elanco, the animal health division of Eli Lilly and Company (NYSE:LLY), today announced an agreement to acquire Lohmann SE (Lohmann Animal Health), a privately-held company headquartered in Cuxhaven, Germany. Lohmann Animal Health is a global leader in the supply of poultry vaccines and also markets a range of feed additives. The acquisition will establish Elanco as a global poultry leader, solidify Elanco's vaccine presence, broaden Elanco's product offerings and significantly augment Elanco's vaccine manufacturing capabilities.
Eli Lilly and Company is engaged in discovering, developing, manufacturing, and marketing products in two business segments: human pharmaceutical products; and animal health products. Co.'s human pharmaceutical products include: cardiovascular, endocrinology, immunology, neuroscience and oncology products. Co.'s animal health products are comprised of products for animals, among others, which include Clynav, a vaccine to control pancreas disease in salmon; Coban®, Maxiban®, and Monteban®, anticoccidial agents for use in poultry; as well as products for companion animals, which include Comfortis®, a chewable tablet that kills fleas and prevents flea infestations on dogs.
Eli Lilly SEC Filing Email Alerts Service
Open the LLY Page at The Online Investor »
Buy (3.27 out of 4)
(ranked higher than approx. 52% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite